Gilead says its COVID-19 drug can help reduce deaths, shorten hospital stays

Gilead Sciences Inc. (GILD, -0.14%) reported on Tuesday that its COVID-19 drug, remdesivir, marketed as Veklury, can help reduce deaths and readmission rates among patients hospitalized with COVID-19 who received the drug shortly after their hospital admission. This finding was based on three studies, and it was observed regardless of disease severity and variant. The treatment was also found to reduce deaths among immunocompromised patients, such as those living with cancer or HIV.

The news of the drug’s efficacy came shortly after Gilead reported another drop in Veklury sales earlier this month. Shares of Gilead inched up 0.3% in the extended session Tuesday after ending the regular trading day down 0.1%.

The study results released by Gilead on Tuesday showed that patients treated with remdesivir, or Veklury, had a lower risk of death compared to those who received placebo. The study also showed that the drug reduced the risk of readmission to the hospital within 28 days of the initial hospital discharge. This was true regardless of disease severity and variant.

In addition, the study found that remdesivir reduced the risk of death among immunocompromised patients, such as those living with cancer or HIV. This finding was particularly notable, as these patients are known to be at a higher risk of severe illness and death due to COVID-19.

Gilead’s findings come at a time when the world is in the midst of a global pandemic. As of April 2021, the World Health Organization reported that there have been over 132 million confirmed cases of COVID-19 worldwide, and over 2.9 million deaths.

The news of the drug’s efficacy is encouraging, and could potentially help to reduce the number of deaths due to COVID-19. Gilead’s findings suggest that remdesivir, or Veklury, is an effective treatment for COVID-19 and could potentially save lives.

The news of the drug’s efficacy has also been a boon for Gilead, as the company’s stock price has seen an increase following the announcement. Gilead’s stock price has been on a steady upward trajectory since the announcement, and is up 0.3% in the extended session Tuesday after ending the regular trading day down 0.1%.

The news of the drug’s efficacy is encouraging, and could potentially help to reduce the number of deaths due to COVID-19. Gilead’s findings suggest that remdesivir, or Veklury, is an effective treatment for COVID-19 and could potentially save lives.

Remdesivir, or Veklury, has been approved for emergency use in over 100 countries and is recommended as a treatment for COVID-19 by the World Health Organization. The drug is administered intravenously and is typically given over the course of five days.

The news of the drug’s efficacy is encouraging, and it is hoped that it will help to reduce the number of deaths due to COVID-19. Gilead’s findings suggest that remdesivir, or Veklury, is an effective treatment for COVID-19 and could potentially save lives. As the world continues to grapple with the pandemic and the search for effective treatments continues, Gilead’s findings could potentially be a game-changer for those fighting the virus.

It is important to note, however, that the findings from Gilead’s studies are still preliminary and more research is needed to confirm the efficacy of remdesivir, or Veklury, as a treatment for COVID-19. In addition, it is also important to note that the drug is not a cure for the virus, and it is still important to practice social distancing, wear a mask, and wash your hands regularly in order to protect yourself and others from the virus.

In conclusion, Gilead’s findings suggest that remdesivir, or Veklury, is an effective treatment for COVID-19 and could potentially save lives. The news of the drug’s efficacy is encouraging, and it is hoped that it will help to reduce the number of deaths due to COVID-19. However, it is important to note that the findings from Gilead’s studies are still preliminary and more research is needed to confirm the efficacy of remdesivir, or Veklury, as a treatment for COVID-19. In addition, it is still important to practice social distancing, wear a mask, and wash your hands regularly in order to protect yourself and others from the virus.

Share:

Related Posts